Acute Ischemic Stroke Diagnosis and Treatment Market By Type (Diagnostics, Treatment), By End User (Hospitals and Clinics, Ambulatory Surgery Centers, Diagnostic Laboratories and Imaging Centers, Others): Global Opportunity Analysis and Industry Forecast,

Acute Ischemic Stroke Diagnosis and Treatment Market By Type (Diagnostics, Treatment), By End User (Hospitals and Clinics, Ambulatory Surgery Centers, Diagnostic Laboratories and Imaging Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


 The acute ischemic stroke diagnosis and treatment market was valued at $5.1 billion in 2022 and is estimated to reach $9.2 billion by 2032, exhibiting a CAGR of 6.1% from 2023 to 2032. 

An acute ischemic stroke (AIS) is a medical emergency characterized by a sudden disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This condition primarily results from the blockage or obstruction of a blood vessel supplying the brain, commonly due to a blood clot. The obstruction prevents adequate blood flow, causing damage to the brain tissue in the affected area. Acute ischemic strokes can manifest with various neurological deficits, such as sudden weakness, numbness, difficulty speaking, and impaired coordination. Thrombolytic medications, such as alteplase, and mechanical interventions like thrombectomy are commonly used to restore blood flow and mitigate the impact of an acute ischemic stroke. 

Acute ischemic stroke (AIS) stands as the fourth leading cause of death and the primary cause of adult disability. This condition typically arises when a blood vessel obstruction occurs, resulting in irreversible brain injury and subsequent focal neurological deficits. The pharmacological approach to treating AIS revolves around intravenous thrombolysis using an alteplase, also known as recombinant tissue plasminogen activator (tPA). Alteplase administered intravenously facilitates thrombolysis by catalyzing the hydrolysis of plasminogen, forming the proteolytic enzyme plasmin. 

The acute ischemic stroke diagnosis and treatment market has experienced significant growth owing to rise in prevalence of ischemic stroke. For instance, according to the World Stroke Organization Global Stroke Fact Sheet 2022, there were over 7.6 million new ischemic strokes each year and globally, over 62% of all incident strokes are ischemic strokes.  

However, high cost of ischemic stroke diagnosis and treatment limits the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the market growth. 

On the other hand, ongoing advancements in treatment options, including thrombolytic medications such as alteplase and innovative mechanical interventions like thrombectomy, drive the growth of the acute ischemic stroke market. These developments contribute to effective and timely management of acute ischemic strokes. 

The acute ischemic stroke diagnosis and treatment market is segmented into type, end user, and region. By type, the market is segregated into diagnosis, and treatment. The diagnosis segment is further categorized into computed tomography, magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The treatment segment is bifurcated into thrombolytic therapy and mechanical thrombectomy. The thrombolytic therapy segment is further classified into tissue plasminogen activator, antiplatelet, and others. The mechanical thrombectomy segment is categorized into stent retriever and aspiration catheter, and combination (stent retriever and aspiration catheter). By end user, the market is divided into hospitals & clinics, diagnostic laboratories & diagnostic imaging centers, and others. 

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). 

Major key players that operate in the acute ischemic stroke diagnosis and treatment market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, GE Healthcare, Koninklijke Philips N.V., Siemens, Abbott Laboratories Medtronic plc, Johnson & Johnson, and Stryker Corporation. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the acute ischemic stroke diagnosis and treatment market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acute ischemic stroke diagnosis and treatment market analysis from 2022 to 2032 to identify the prevailing acute ischemic stroke diagnosis and treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the acute ischemic stroke diagnosis and treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global acute ischemic stroke diagnosis and treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Diagnostics
Technology
Computed Tomography
Magnetic Resonance Imaging
Carotid Ultrasound
Cerebral Angiography
Electrocardiography
Echocardiography
Others
Treatment
Type
Thrombolytic Therapy◦ Type
Mechanical Thrombectomy◦ Type

By End User

Hospitals and Clinics
Ambulatory Surgery Centers
Diagnostic Laboratories and Imaging Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Boehringer Ingelheim International GmbH
AstraZeneca plc
Abbott Laboratories
Stryker Corporation.
Siemens
Medtronic plc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Koninklijke Philips N.V.
GE Healthcare

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in incidence of stroke
3.4.1.2. Advancements in imaging technologies
3.4.1.3. Innovations in treatment option
3.4.2. Restraints
3.4.2.1. High cost of innovative therapies
3.4.3. Opportunities
3.4.3.1. High market growth potential in emerging markets
CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Diagnostics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Diagnostics Acute Ischemic Stroke Diagnosis and Treatment Market by Technology
4.3. Treatment
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Treatment Acute Ischemic Stroke Diagnosis and Treatment Market by Type
4.3.4.1. Thrombolytic Therapy Acute Ischemic Stroke Diagnosis and Treatment Market by Type
4.3.4.2. Mechanical Thrombectomy Acute Ischemic Stroke Diagnosis and Treatment Market by Type
CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals and Clinics
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Ambulatory Surgery Centers
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Diagnostic Laboratories and Imaging Centers
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. AstraZeneca plc
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. F. Hoffmann-La Roche Ltd.
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. GE Healthcare
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Boehringer Ingelheim International GmbH
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Koninklijke Philips N.V.
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Abbott Laboratories
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Siemens
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Medtronic plc
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Johnson & Johnson
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Stryker Corporation.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL DIAGNOSTICS ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 04. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL TREATMENT ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 06. GLOBAL THROMBOLYTIC THERAPY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 07. GLOBAL MECHANICAL THROMBECTOMY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 09. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 20. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 21. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 25. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 26. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 29. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 34. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 38. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 42. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 47. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 50. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 56. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 57. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 61. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 65. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 66. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 67. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 68. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 70. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 71. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 72. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 73. GE HEALTHCARE: KEY EXECUTIVES
TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 75. GE HEALTHCARE: PRODUCT SEGMENTS
TABLE 76. GE HEALTHCARE: SERVICE SEGMENTS
TABLE 77. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 78. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 82. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 83. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 84. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
TABLE 85. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 86. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 89. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 91. SIEMENS: KEY EXECUTIVES
TABLE 92. SIEMENS: COMPANY SNAPSHOT
TABLE 93. SIEMENS: PRODUCT SEGMENTS
TABLE 94. SIEMENS: PRODUCT PORTFOLIO
TABLE 95. SIEMENS: KEY STRATERGIES
TABLE 96. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 97. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 98. MEDTRONIC PLC: PRODUCT SEGMENTS
TABLE 99. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 100. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 101. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 102. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 103. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 104. STRYKER CORPORATION.: KEY EXECUTIVES
TABLE 105. STRYKER CORPORATION.: COMPANY SNAPSHOT
TABLE 106. STRYKER CORPORATION.: PRODUCT SEGMENTS
TABLE 107. STRYKER CORPORATION.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET BY REGION, 2022 AND 2032(%)
FIGURE 20. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 21. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 23. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 24. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 25. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 26. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 27. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 28. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 29. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 30. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 31. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 32. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 33. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 35. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 36. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43. COMPETITIVE DASHBOARD
FIGURE 44. COMPETITIVE HEATMAP: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET
FIGURE 45. TOP PLAYER POSITIONING, 2022
FIGURE 46. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. GE HEALTHCARE: NET REVENUE, 2021-2022 ($MILLION)
FIGURE 51. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. GE HEALTHCARE: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. KONINKLIJKE PHILIPS N.V.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 58. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. SIEMENS: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. SIEMENS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 65. SIEMENS: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. SIEMENS: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
FIGURE 68. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 69. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 70. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 72. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 74. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 75. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings